OF SHARED RESOURCE Since the founding of the Pharmacology Analytical Core in 1985, the primary mission of the Core has been to enable the inclusion of critical pharmacological endpoints in the design of clinical trials and preclinical studies, and stimulate new hypotheses and areas of investigation by providing low-cost, state-of-the-art services. The purpose of the Core is to: 1) provide users with expertise in pharmacological trial design, analytical method development, quantitative assays, pharmacokinetic data analysis, and data interpretation in a centralized, dedicated and experienced facility;2) provide services in real time;3) minimize cost and effort for Cancer Center investigators;4) prevent duplication of equipment, technical effort and analytical and pharmacokinetic analysis expertise for the Cancer Center by providing flexible assignment of personnel and equipment. The Core resource provides state-of-the-art equipment, facilities, and expertise in pharmacological trial design, analytical quantitation, and data analysis in approximately 1000 square footage of space on the first floor of the Bunting-Blaustein Cancer Research Building. The location of the Core is adequate both in size and location to meet the needs of the Cancer Center investigators to investigate drug metabolism and disposition and the pharmacodynamics and pharmacogenetics of anticancer agents.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA006973-48
Application #
8117663
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2010-05-01
Budget End
2011-04-30
Support Year
48
Fiscal Year
2010
Total Cost
$233,892
Indirect Cost
Name
Johns Hopkins University
Department
Type
DUNS #
001910777
City
Baltimore
State
MD
Country
United States
Zip Code
21218
Peprah, Sally; Curreiro, Frank C; Hayes, Jennifer H et al. (2018) A spatiotemporal analysis of invasive cervical cancer incidence in the state of Maryland between 2003 and 2012. Cancer Causes Control 29:445-453
Springer, Simeon U; Chen, Chung-Hsin; Rodriguez Pena, Maria Del Carmen et al. (2018) Non-invasive detection of urothelial cancer through the analysis of driver gene mutations and aneuploidy. Elife 7:
Handy, Catherine E; Antonarakis, Emmanuel S (2018) Sipuleucel-T for the treatment of prostate cancer: novel insights and future directions. Future Oncol 14:907-917
Popovic, Aleksandra; Jaffee, Elizabeth M; Zaidi, Neeha (2018) Emerging strategies for combination checkpoint modulators in cancer immunotherapy. J Clin Invest 128:3209-3218
Dean, Lorraine T; Schmitz, Kathryn H; Frick, Kevin D et al. (2018) Consumer credit as a novel marker for economic burden and health after cancer in a diverse population of breast cancer survivors in the USA. J Cancer Surviv 12:306-315
Zhang, Jiajia; Wolfgang, Christopher L; Zheng, Lei (2018) Precision Immuno-Oncology: Prospects of Individualized Immunotherapy for Pancreatic Cancer. Cancers (Basel) 10:
Leadem, Benjamin R; Kagiampakis, Ioannis; Wilson, Catherine et al. (2018) A KDM5 Inhibitor Increases Global H3K4 Trimethylation Occupancy and Enhances the Biological Efficacy of 5-Aza-2'-Deoxycytidine. Cancer Res 78:1127-1139
Danilova, Ludmila; Anagnostou, Valsamo; Caushi, Justina X et al. (2018) The Mutation-Associated Neoantigen Functional Expansion of Specific T Cells (MANAFEST) Assay: A Sensitive Platform for Monitoring Antitumor Immunity. Cancer Immunol Res 6:888-899
Jackson, Sadhana; Weingart, Jon; Nduom, Edjah K et al. (2018) The effect of an adenosine A2A agonist on intra-tumoral concentrations of temozolomide in patients with recurrent glioblastoma. Fluids Barriers CNS 15:2
Dejea, Christine M; Fathi, Payam; Craig, John M et al. (2018) Patients with familial adenomatous polyposis harbor colonic biofilms containing tumorigenic bacteria. Science 359:592-597

Showing the most recent 10 out of 2393 publications